Dasatinib Clinical Trials

24 actively recruiting trials across 11 locations

Also known as: 6-MP, Asparaginase, BMS 354825, BMS-354825, BMS354825, Cyclophosphomide, Cytarabine, Dasatinib Hydrate, Dasatinib Monohydrate, Dasatinib Zentiva, Daunorubicin, Dexamethasone, Methotrexate, SPRYCEL, Sprycel, Sprycel®, Vincristine, sophoretin, sprycel

Filter by location:

Other9 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Phase 2

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

Phase 2

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Phase 1/2

Newly-diagnosed Pediatric T-cell ALL Protocol

Phase 2/3

Pilot Trial for Treatment of Recurrent Glioblastoma

Early 1

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

Phase 2

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

Birmingham, Alabama3 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 3

KRT-232 and TKI Study in Chronic Myeloid Leukemia

University of Alabama Birmingham

Phase 1/2

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

University of Alabama/Children's of Alabama

Phase 2

Chicago, Illinois2 trials

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

University of Chicago Comprehensive Cancer Center

Phase 1

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago Medical Center

Phase 2

Rochester, Minnesota2 trials

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic in Rochester

Phase 2

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

Mayo Clinic in Rochester

Early 1

San Diego, California1 trial

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Rady Children's Hospital

Phase 2

San Francisco, California1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

University of California, San Francisco (UCSF)

Phase 1

Ann Arbor, Michigan1 trial

Asciminib Roll-over Study

Michigan Med University of Michigan

Phase 4

Detroit, Michigan1 trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The Barbara Ann Karmanos Cancer Institute

Phase 2

St Louis, Missouri1 trial

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Washington University School of Medicine

Phase 2

Tulsa, Oklahoma1 trial

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Saint Francis Children's Hospital

Phase 2

Portland, Oregon1 trial

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

OHSU Knight Cancer Institute

Phase 1

Houston, Texas1 trial

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.